#finerenone effect in DM-free patients with
- eGFR of 25-60 ml/min x 1.73 m^2 & UACR of 200-500 mg/g
or
- eGFR of 25-90 ml/min x 1.73 m^2 & UACR of 500-3500 mg/g
#CKD
Finerenone in Persons with Chronic Kidney Disease without Diabetes | New England Journal of Medicine www.nejm.org/doi/full/10....
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist,
improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic
kidney disease (CKD)...
